Paracetamol is the drug most commonly taken as an overdose and the main cause of acute liver failure in the UK. The estimates of the number of overdoses including paracetamol range up to 70000 per annuml. The great majority of these patients show no sign of important liver or kidney damage and are discharged from hospital within a few days of presentation. The percentage who receive Nacetylcysteine is unknown, but this treatment would represent the main cost difference in the management of paracetamol and other ultimately innocuous drug overdoses. However, resource implications are vastly greater for the 400-500 patients per year who develop severe liver damage and require management in specialist liver centres.
The guidelines for transfer to a specialist unit after a paracetamol overdose are outlined in Table 1 . About 38% of patients transferred to specialist liver units do not deteriorate significantly after arrival and are fit to return to the referring hospital within 3-4 days2. A small group of patients develop renal failure as the dominant manifestation of the paracetamol overdose and these may require renal support for up to 6 weeks. The correlation between disorders of coagulation [prothrombin time or international normalized ratio (INR)] and outcome is imprecise and there is considerable overlap between the derangements seen in this group and those who progress to grade [3] [4] encephalopathy. Metabolic acidosis is the only early prognostic indicator that is strongly indicative of a poor outcome, but this lacks sensitivity and was present in only about a third of patients who ultimately died3. The lack of precision in predicting outcome, combined with the potential for rapid progression to advanced encephalopathy and its associated complications, makes this level of 'unnecessary transfer' unavoidable, especially if the potential for transplantation is to be fully realized; these patients have a very short window period during which they are suitable candidates for liver transplantation4.
The typical patient transferred to a specialist unit is young (average age 29 years), single (57%), female (56%), and taking the first overdose (62%)2. Of those who develop advanced encephalopathy (grades 3 and 4) 50-55% will survive with medical management, 35% will die, and 10-15% will undergo emergency liver transplantation2'5.
The survivors with medical management typically spend 7-10 days in intensive care and a further 2-4 weeks in hospital, before ultimately regaining full physical health without sequelae or the need for drug therapy. The number of patients undergoing transplantation represents 41-43% of those listed for transplantation because they meet the criteria in Table 2 and lack medical or psychosocial contraindications4'6. The remaining patients die or develop contraindications to transplantation before an organ becomes available4'6. The survival rates in those receiving liver grafts have ranged between 66% and 76%2,4,6. These patients do not return to normality but must adapt to the discipline and constraints common to liver transplant recipients. They will probably require anti-rejection medication for the remainder of their lives and the cost of this and the attendant monitoring is great. The cost to the National Health Service (NHS) of treating the cohort who develop severe liver damage is £6-8 million a year and the cost of maintaining a liver transplant recipient is between £3000 and £5000 a year.
Auxiliary liver transplantation has the potential to confer the benefits of transplantation without the need for longterm maintenance of the graft once the native organ has regenerated. This approach is in theory ideal for paracetamol-induced acute liver failure because the native liver regenerates to completely normal morphology, but the Prevention of paracetamol hepatotoxicity has the potential to save lives, make more organs available for elective transplantation and reduce demands on valuable intensive care resources. The dose-dependent nature of the hepatotoxicity and the parasuicidal, rather than suicidal, intent in the majority of cases suggest that a considerable proportion could be prevented. Since paracetamol is marketed in the UK as an inexpensive analgesic in quantities of up to 50 g it is widely, available when parasuicidal gestures are contemplated, and this may contribute to its prominent profile in this regard. Half of all cases of severe paracetamol hepatotoxicity were impulsive or reactive to life-events, and only 4% of these patients left suicide notes2. However, even amongst the patients taking overdoses against a background of depression, only 8% left suicide notes, so there may also be an impulsive element to the overdose in these cases2.
Preventive strategies could address the ease of access to paracetamol, the way it is packaged, or the availability of methionine as a hepatoprotective agent. Paracetamol hepatotoxicity could be largely abolished by an Act of Parliament making the drug available only on prescription. However, this would deprive the general population of easy access to a cheap, effective and safe analgesic. The late UK Government consulted on a proposal to restrict the sale of paracetamol to quantities of 6 g in general outlets and 15 g in pharmacies, while multiple packs would be available at a pharmacist's discretion for chronic and recurrent illnesses9.
These quantities overlap with the range of observed toxic doses (5-210 g), although in one study only 8% of patients with severe liver damage had taken less than 12 g2. This would suggest that restriction of the quantities easily impulsiveness typical of many overdoses may be obstructed by presenting the tablets in blister packs so that the time needed to punch them out allows the implications of the act to register.
An alternative approach is the addition of methionine to paracetamol tablets to reduce the toxicity in overdose. Methionine has a similar function to N-acetylcysteine: it is a substrate that allows glutathione repletion, thus protecting against the hepatotoxicity caused by an unstable metabolite of paracetamol. Such preparations are available but they represent a tiny proportion of the total sales of paracetamol and are used mainly in controlled environments. This approach cannot be expected to have an impact on the burden of overdoses unless inclusion of methionine in all paracetamol preparations becomes obligatory. Early problems with palatability and inflated cost are said to have been overcome, although the existing preparations are considerably more expensive than simple paracetamol. However, it must be conceded that the efficacy of this approach has not yet been demonstrated and there is considerable opposition to the imposition of obligatory paracetamol/methionine combinations.
Given the scale of the problem caused by paracetamol toxicity and the availability of preventive measures, it is hard to resist the conclusion that the status quo is unsustainable. Unfortunates intent on committing suicide are not going to benefit from change, nor is the number of parasuicidal gestures likely to fall substantially. However, few of the alternative methods favoured for parasuicides possess the 'sting in the tail' so characteristic of paracetamol self-poisoning. Thus, even if the parasuicide burden is merely shifted to another aspect of healthcare, the overall benefit to a young population and to the NHS could be enormous.
Inadvertent paracetamol-induced hepatotoxicity accounted for 8% of cases admitted to the Liver Unit at King's College Hospital between 1987 and 19932. This may result from excessive dosing through lack of realization of the maximum recommended dose (despite explicit labelling) or lack of awareness of the presence of paracetamol in multiple drug combinations. Educational initiatives to promote awareness of these issues are necessary if the explicit advice on drug packaging and information sheets is to be effective. Chronic alcohol consumers, malnourished individuals and patients with enzyme induction secondary to antiepileptic therapy are also at risk from paracetamol taken with therapeutic intent1I 12. In one series of 67 patients with liver damage attributed to therapeutic usage, 64% were considered to be alcohol abusers12. This observation has resulted in a modification of the treatment nomogram widely used to determine the need for N-acetylcysteine, so that the threshold has been halved for these cases.
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